Skip to main content
. Author manuscript; available in PMC: 2020 Jun 9.
Published in final edited form as: Nature. 2019 Dec 9;577(7789):244–248. doi: 10.1038/s41586-019-1786-y

Extended Data Figure 3: Phage ΦKZ resists targeting by heterologous Type II-A and V-A CRISPR-Cas systems.

Extended Data Figure 3:

a, Strain PAO1 was engineered to express the Type II-A Cas9 protein and distinct single guide RNAs (sgRNAs) targeting the indicated phage. Plaque assays were conducted as in Figure 1a. b, Strain PAO1 was engineered to express the Type V-A Cas12a protein and distinct crRNAs against the indicated phage. Plaque assays were conducted as in Figure 1a. All plaque assays replicated ≥ 2 times with similar results.